Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

ONCOLOGY Table Of Contents

Use of Bisphosphonates in the Treatment of Prostate Cancer

September 1, 2000
  • Karin B. Olson, PA-C
  • Kenneth J. Pienta, MD

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.

  • READ >>
  • Add new comment

Cancer Treatment Bill

September 1, 2000

Politics may have a little something to do with nearing congressional passage of a bill (S. 662/H.R. 1070) that would allow states to provide medical treatment via Medicaid for low-income women who have been diagnosed with breast or cervical cancer through the CDC’s National Breast and Cervical Cancer Early Detection Program. In the decade that the program has existed, about 1 to 1.5 million women have been screened, with 6,000 cases of breast cancer and 500 of cervical cancer being found. But once diagnosed, these women, whose incomes are too high for Medicaid and who do not have personal health insurance, have to search for “donated” medical care. The Senate bill, originally sponsored by now-deceased Sen. John Chafee, passed the Senate Finance Committee at the end of June. It now goes to the floor, where passage seems assured. The House bill, which passed in May, is sponsored by Rep. Rick Lazio (R-NY), now knee-deep in a high-profile New York Senate race with Hillary Clinton. House Republicans are eager to give Lazio something to talk about. The cost of the measure will be about $50 million a year to the federal government, which contributes about $3 for each $1 that states contribute to the Medicaid pot. Nonetheless, the Senate Finance Committee was concerned enough about a potential precedent to include in its report a sentence saying that this benefit “shall not be viewed as a precedent for extending Medicaid eligibility body-part by body-part.”

  • READ >>
  • Add new comment

Cancer, Unproven Therapies, and Magic

September 1, 2000
  • Barrie R. Cassileth, MS, PhD
  • Andrew Vickers, PhD

Commonly used by cancer patients, unproven therapies are treatments that the practitioner claims can alter the disease process although there is no proof to support the claim. The reasons for the popularity of uproven

  • READ >>
  • Add new comment

Recent Developments in Chemoradiotherapy for Locally Advanced Cancer of the Cervix

September 1, 2000
  • Nina A. Mayr, MD
  • Anil K. Sood, MD

Patients with locally advanced cervical cancer comprise a significant proportion of the total population with cervical cancer, particularly in developing countries. The inability to control pelvic tumors is still a significant

  • READ >>
  • Add new comment

Pharmacology and Clinical Status of Capecitabine

September 1, 2000
  • I. Craig Henderson, MD

In treating cancer, discovering new ways to use or modify old drugs can sometimes be as valuable as the identification of new drugs. This point is elegantly illustrated in Dr. Schilsky’s article about capecitabine (Xeloda), a prodrug that leads to high intratumoral levels of fluorouracil (5-FU).

  • READ >>
  • Add new comment

Optimal Use of the Newer Antifungal Agents

September 1, 2000

The prevention and treatment of invasive fungal infections is being improved by the relatively recent introduction of new antifungal agents. While some of these agents offer better efficacy, others are proving their value more in improved tolerability, said John R.

  • READ >>
  • Add new comment

New Awards Spotlight Courage of Cancer Survivors

September 1, 2000

Surviving cancer is a joyous thing in itself. A new awards program will spotlight that joy and share the stories of 12 survivors who are “everyday heroes,” in an effort to help others who are struggling with the disease.

  • READ >>
  • Add new comment

Hematopoietic Cell Transplantation, Second Edition

September 1, 2000
  • E. Donnall Thomas, MD
  • Karl G. Blume, MD
  • Stephen J. Forman, MD
  • Wendy Stock, MD

Hematopoietic Cell Transplantation, edited by Drs. Thomas, Blume, and Forman, is an excellent updated second edition of their comprehensive textbook designed for both practitioners involved in transplantation and those interested in the science of stem-cell transplantation.

  • READ >>
  • Add new comment

Update on Adjuvant Chemotherapy for Early Breast Cancer

September 1, 2000
  • Aman U. Buzdar, MD
  • Gabriel N. Hortobagyi, MD, FACP

Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including

  • READ >>
  • Add new comment

Cancer, Unproven Therapies, and Magic

September 1, 2000
  • James M. Metz, MD
  • Martin Rosenthal, MD
  • David I. Rosenthal, MD

Commonly used by cancer patients, unproven therapies are treatments that the practitioner claims can alter the disease process although there is no proof to support the claim. The reasons for the popularity of uproven

  • READ >>
  • Add new comment

Update on Adjuvant Chemotherapy for Early Breast Cancer

September 1, 2000
  • Clifford A. Hudis, MD

Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including

  • READ >>
  • Add new comment

Use of Bisphosphonates in the Treatment of Prostate Cancer

September 1, 2000
  • Richard Theriault, DO, MBA

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.

  • READ >>
  • Add new comment

Longer Time to Tumor Progression With Exemestane vs Tamoxifen in Advanced Breast Cancer

September 1, 2000

Initial data from a phase II study of exemestane (Aromasin) as first-line treatment of advanced breast cancer in postmenopausal women suggest that the new agent may extend the time that patients remain free of tumor growth compared to tamoxifen (Nolvadex).

  • READ >>
  • Add new comment

Update on Adjuvant Chemotherapy for Early Breast Cancer

September 1, 2000
  • Mark N. Levine, MD, MSC, FRCP
  • Timothy J. Whelan, BM, BCH, MSC

Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including

  • READ >>
  • Add new comment

New Drug Delivery System May Offer Clinical Advantages in Prostate Cancer Treatment

September 1, 2000

A potential new treatment under development for prostate cancer may offer clinical advantages, researchers reported at the annual meeting of the American Urological Association in Atlanta.

  • READ >>
  • Add new comment

Preclinical Pharmacologic Basis for Clinical Use of rhIL-11 as an Effective Platelet-Support Agent

September 1, 2000
  • Tomas Berl, MD
  • Ullrich Schwertschlag, MD, PhD

Preclinical studies have shown that rhIL-11, also known as oprelvekin (Neumega), stimulates early and later stages of megakaryocytopoiesis (including proliferation and differentiation of megakaryocyte precursors and maturation of megakaryocytes), to

  • READ >>
  • Add new comment

Pharmacology and Clinical Status of Capecitabine

September 1, 2000
  • Alex A. Adjei, MD, PhD

In this issue of Oncology, Dr. Schilsky has provided a comprehensive yet concise review of the pharmacology of the fluoropyrimidines and, in particular, capecitabine (Xeloda).

  • READ >>
  • Add new comment

ASCO to Push Medicare on Fee Issue

September 1, 2000

The Health Care Financing Administration (HCFA) proposed increased reimbursement for two heavily used chemotherapy administration codes (90408 and 90410), but not nearly as much as ASCO had been pushing for. AMA’s relative value update committee (RUC) voted to accept ASCO’s data justifying an increase in the clinical staff time related to an oncologist’s expenses associated with both codes.This recommendation was forwarded to HCFA. Clinical staff time—the time a nurse or staff spends giving chemotherapy or educating a patient—is figured into the “practice expense,” which, with “physician work” (time spent face-to-face with the patient) and “malpractice expense,” is part of the formula for determining a CPT code’s relative value, which dictates reimbursement. However, HCFA slightly lowered the clinical staff times recommended by the RUC. Julie Taylor, deputy director of public policy for ASCO, says the group will be submitting comments to HCFA to accept the RUC recommendation. HCFA’s final decision will go into effect on January 1, 2001.

  • READ >>
  • Add new comment

Update on Adjuvant Chemotherapy for Early Breast Cancer

September 1, 2000
  • Nicole J. Mccarthy, MBBS
  • Sandra M. Swain, MD, FACP

Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer and, as such, has saved many lives. Worldwide, adjuvant chemotherapy has benefitted all groups tested, including

  • READ >>
  • Add new comment

Cancer, Unproven Therapies, and Magic

September 1, 2000
  • Simon Wein, MD

Commonly used by cancer patients, unproven therapies are treatments that the practitioner claims can alter the disease process although there is no proof to support the claim. The reasons for the popularity of uproven

  • READ >>
  • Add new comment

Recent Developments in Chemoradiotherapy for Locally Advanced Cancer of the Cervix

September 1, 2000
  • Robert Y. Kim, MD
  • Ronald D. Alvarez, MD

Patients with locally advanced cervical cancer comprise a significant proportion of the total population with cervical cancer, particularly in developing countries. The inability to control pelvic tumors is still a significant

  • READ >>
  • Add new comment

Dose Reductions and Delays: Limitations of Myelosuppressive Chemotherapy

September 1, 2000
  • Mitchell S. Cairo, MD

Thrombocytopenia occurs at various grades of severity in patients with nonmyeloid malignancies undergoing chemotherapy with myelosuppressive agents. Frequently, it is the major dose-limiting hematologic toxicity, especially in the treatment of potentially curable malignancies such as leukemia, lymphomas, and pediatric cancers.

  • READ >>
  • Add new comment

rhIL-11 for the Prevention of Dose-Limiting Chemotherapy-Induced Thrombocytopenia

September 1, 2000
  • Razelle Kurzrock, MD

In order to derive maximum benefit from treatment with chemotherapeutic agents, adherence to the established chemotherapy dose and schedule is imperative.

  • READ >>
  • Add new comment

Clinical Efficacy of rhIL-11

September 1, 2000
  • Craig H. Reynolds, MD

Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy

  • READ >>
  • Add new comment

Pharmacology and Clinical Status of Capecitabine

September 1, 2000
  • Richard L. Schilsky, MD

Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells. Selective tumor activation of 5´-deoxy-5-fluorouridine,

  • READ >>
  • Add new comment

Tamoxifen Approved for Use in Patients With Ductal Carcinoma In Situ

September 1, 2000

AstraZeneca announced recently that the US Food and Drug Administration (FDA) has approved use of its breast cancer drug tamoxifen (Nolvadex) to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation.

  • READ >>
  • Add new comment

Pharmacology and Clinical Status of Capecitabine

September 1, 2000
  • Richard L. Schilsky, MD

Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells. Selective tumor activation of 5´-deoxy-5-fluorouridine,

  • READ >>
  • Add new comment

IG Guidelines on Individual Physicians and Small Practices

September 1, 2000

Individual physicians and those in small group practices are urged to begin implementing internal audit procedures for “high risk” billing operations.

  • READ >>
  • Add new comment

Use of Bisphosphonates in the Treatment of Prostate Cancer

September 1, 2000
  • James R. Berenson, MD, FACP

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.

  • READ >>
  • Add new comment

Tolerability and Side-Effect Profile of rhIL-11

September 1, 2000
  • John W. Smith Ii, MD

Safety data from two randomized phase II and one abbreviated phase III placebo-controlled, double-blind clinical studies in adult patients with nonmyeloid malignancies indicate that recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) has an acceptable toxicity profile as therapy for the mitigation of chemotherapy-induced thrombocytopenia.

  • READ >>
  • Add new comment

Camptosar Plus Cisplatin Increase Survival in Small-Cell Lung Cancer Study

September 1, 2000

Irinotecan (Camptosar) in combination with cisplatin (Platinol) increased survival, compared with the current standard treatment for patients with extensive small-cell lung cancer, according to data from a phase III study presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

  • READ >>
  • Add new comment

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".